UPM permanently closes its Chapelle newsprint mill
(UPM, Helsinki, 16.07.2020 at 11:00 EET) – UPM will permanently cease production at its Chapelle newsprint mill in Grand-Couronne, France today. The consultation process with employee representatives was completed on June 15th, 2020 according to French legislation and approved by French authorities on July 15th, 2020.
The closure impacts 228 people. UPM offers support to employees in order to alleviate the effects caused by staff reductions in relation to the closing of the mill.
With the closure of the mill UPM will reduce a total of 240.000 tonnes of its newsprint paper capacity.
“After UPM announced the intention to sell the Chapelle mill in September we started an active sales process and have been in discussions with interested parties since. However, we have not received binding offers by potential buyers. Consequently, we decided to close the mill, while at the same time working with employee representatives to mitigate the social impact on our employees. We remain committed to selling the mill assets if we receive a suitable offer,” says Anu Ahola, Senior Vice President, News & Retail, UPM Communication Papers.
UPM recognizes restructuring charges in total of EUR 78 million, whereof EUR 61 million as cash costs. EUR 45 million was booked as items affecting comparability in Q1 2020 and EUR 33 million in Q2 2020. The action will result in annual savings of approximately EUR 30 million.
For further information please contact:
Jean Kubiak, General Manager, UPM Chapelle, (through Pyksis: tel. +33 614888577 or +33 663677511)
UPM, Media Relations
Mon-Fri 9:00-16:00 EET
tel. +358 40 588 3284
media@upm.com
About UPM Chapelle
UPM Chapelle manufactures newsprint papers with an annual capacity of 240,000 tonnes. Situated in Grand Couronne, France the mill currently employs 228 people, operating one paper machine.
About UPM Communication Papers
UPM Communication Papers is the world's leading producer of graphic papers, offering an extensive product range for advertising and publishing as well as home and office uses. The high performing papers and service concepts of UPM add value to our customers' businesses, while actively fulfilling demanding environmental and social responsibility criteria. With headquarters in Germany, UPM Communication Papers employs approximately 7,700 people. More about UPM Communication Papers and its products at www.upmpaper.com
Follow UPM Communication Papers on Twitter | LinkedIn
UPM
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 18,700 people worldwide and our annual sales are approximately EUR 10.2 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com
Follow UPM on Twitter | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Baloise Group Signs Contract to Fulfill IFRS 17 Reporting and Compliance Requirements With Systemorph Solution24.11.2020 07:00:00 CET | Press release
ZURICH, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Systemorph, a leader in data management solutions for insurance and banking, today announced that it signed a contract with Baloise Group to implement and run its IFRS 17 solution for Baloise Group to comply with the new international reporting standard. The Systemorph IFRS 17 solution includes all group-wide calculation functions required to comply with the accounting standard and will be used by Baloise Group for its IFRS 17 reporting. Baloise Group chose the Systemorph solution because it delivers an important part in the overall auditable end-to-end reporting process. This easy, transparent, consistent and custom-built solution to meet the specific Baloise Group requirements enhances the collaboration between actuarial, finance and IT departments. After the implementation phase Systemorph will provide the IFRS 17 solution as Software-as-a-Service (SaaS) for Baloise Group. About Systemorph: Founded in Zurich in 2011 the Swiss-ba
Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person24.11.2020 07:00:00 CET | Press release
Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis) Roche also provides an update on the sNDA filing for Xofluza in the paediatric setting Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis. “With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re hopeful that reducing the burden of influenza ma
ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids24.11.2020 07:00:00 CET | Press release
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT)200 mg once daily with concomitant ABT for long-term use (beyond 6 months)200 mg once daily for short-term use, in particular when rapid reduction in fibroid volume is desired ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in 1H:21 GENEVA, Switzerland and BOSTON, MA (November 24, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for YSELTY® (linzagolix 100mg and linzagolix 200mg) for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids. “The MAA submission is a
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event24.11.2020 07:00:00 CET | Press release
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth drivers now contributing to 48% of Innovative Medicines sales; upcoming launches expected to lay the foundation for future salesexpansion Advancing leading pipeline based on scale, innovation and value which will fuel growth in the mid- to long-termand help offset patent cliffs Committed to driving consistent margin expansion, Innovative Medicinesexpected to reach high 30s in the mid-term. Target for Novartis Technical Operations productivity program starting in 2021 increased from USD 1.5bn to USD 2bn Laying the foundations for sectorleadership in the ESG space Initiating share buyback of up to USD 2.5bn, highlighting confidence in growth Basel, November24, 2020 — Novartis is hosting today its annual Meet Novartis Management event giving investors and industry analysts the opportunity to meet with ke
Awilco Drilling PLC: Awilco Drilling Reports Q3 2020 results24.11.2020 07:00:00 CET | Press release
Awilco Drilling PLC reported contract revenue of USD 10.6 million (USD 6.4 million Q2), EBITDA USD 1.7 million (USD 1.5 million loss in Q2) and a net loss of USD 1.0 million (USD 4.6 million loss in Q2). Revenue efficiency was 100% during the standard day rate work in the quarter (Q2 fixed price work only). Operational uptime was 100% during the quarter during the standard day rate work in the quarter (Q2 fixed price work only). Contract backlog at the end of Q3 was approximately USD 15.2 million (USD 19.4 million Q2). Please see attached for the Q3 2020 report. A digital presentation will be held today, on 24 November 2020 at 12:00 UK time (13:00pm CET / 07:00 EST). The presentation will be available for download on the Investor Relations section (go to "Press Releases") at www.awilcodrilling.com prior to the meeting. There will be a Q&A session after the presentation. To join the digital meeting, please click this link or copy and paste the following address into your browser: https:
Selvita to acquire Fidelta from Galapagos23.11.2020 22:15:00 CET | Press release
-Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe - Acquisition substantially expands Selvita’s integrated drug discovery services offering Transaction will almost double Selvita’s revenues Enterprise value of € 31.2M to be paid in cash Fidelta to continue performing drug discovery services for Galapagos for the next five years Mechelen, Belgium and Krakow, Poland – 23 November 2020, 22.15 CET – Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] – announced today that they have signed an agreement under which Selvita will acquire 100% of the outstanding shares in Fidelta d.o.o. for an enterprise value of €31.2M plus the customary adjustments for net cash and working capital. Fidelta is a contract research organization within the Galapagos Group of companies, with core scientific competences in inflammation, fibrosis, and anti-infectives. It currently employs 181 employees, including over 150 highly experienced